CD20

In humans CD20 is encoded by the MS4A1 gene localized to 11q12. The gene is 16 kbp long and consists of 8 exons. There are at least 3 mRNA transcripts (resulting from alternative splicing), that are all translated into an identical full-length CD20 protein product. MS4A1 gene is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and non-lymphoid tissues. == Structure ==

CD20 is a transmembrane protein consisting of four hydrophobic transmembrane domains, one intracellular domain and two extracellular loops. There are three different forms of CD20 according to variable phosphorylation. CD20 is located on the cell surface as homo-dimeric and homo-tetrameric oligomers. It is associated with other cell-surface and cytoplasmic proteins connected to the signal transduction (CD53, CD81, CD82). CD20 is also known to be physically coupled to major histocompatibility complex class II (MHCII), CD40 and B-cell receptor (BCR). == Function ==

The biological function of CD20 as well as its natural ligand is not fully elucidated. CD20 deletion in mice does not impair B-cell differentiation, isotype switch, maturation, proliferation or tissue localization. However, CD20−/− mice show decreased humoral immunity responses in both T-cell dependent and T-cell independent manner. The interleukin 4 (IL-4) produced by T cells can induce CD20 expression via STAT6 transcription factor. == Expression ==

CD20 is expressed on all stages of B cell development from pre-B cells in the bone-marrow through immature, naive, mature and memory cells in lymphoid tissues and blood. The expression is lost on plasma blasts and plasma cells. CD20 is a marker of B cell malignancies. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Immunohistochemistry can be used to determine the presence of CD20 on cells in histological tissue sections. Because CD20 remains present on the cells of most B-cell neoplasms, and is absent on otherwise similar appearing T-cell neoplasms, it can be very useful in diagnosing conditions such as B-cell lymphomas and leukaemias. However, the presence or absence of CD20 in such tumours is not relevant to prognosis, with the progression of the disease being much the same in either case. CD20 positive cells are also sometimes found in cases of Hodgkins disease, myeloma, and thymoma. Even though B cells represent the majority of CD20+ cells, a subset of CD3+ T cells also expresses CD20. CD20+ T cells are mostly CD8+ effector memory T cells with proinflammatory features. Further work is needed to understand the contribution of these cells to immune responses. == Anti-CD20 monoclonal antibodies ==

The targeting of CD20 molecule is highly effective way to deplete B-cell populations. • Complement dependent cytotoxicity Anti-CD20 mAbs interact with C1q complement protein, leading to classical complement pathway activation and eventual complement dependent cytotoxicity. • Fcγ receptor mediated effects Fcγ receptors expressed on neutrophils, NK cells or macrophages interact with Fc part of anti-CD20 mAb. The interaction leads to enhanced cytotoxic activity of NK cells (antibody-dependent cell-mediated cytotoxicity) and phagocytosis by macrophages and neutrophils (antibody-dependent cell-mediated phagocytosis). • Hyper-crosslinking The accumulation of anti-CD20 mAbs on the cell surface may cause caspase-dependent apoptotic cell death. In clinical practise Examples of anti-CD20 mAbs and their approval status: Although phase II trials for the use of Rituximab in myalgic encephalomyelitis showed promising results, these could not be replicated in a large randomized controlled trial and preliminary results from a Phase III trial were negative. Additional anti-CD20 antibody therapeutics under development (phase II or III clinical trials in 2008) include : • Obinutuzumab for systemic lupus erythematosus, • Ocaratuzumab for follicular lymphoma and rheumatoid arthritis, • TRU-015 (by Trubion), (discontinued in 2010) • IMMU-106 (veltuzumab). for non-Hodgkin's lymphoma or (2015) immune thrombocytopenia. == Clinical significance ==

Diabetes mellitus A link between the immune system's B cells and diabetes mellitus has been determined. In cases of obesity, the presence of fatty tissues surrounding the body's major organ systems results in cell necrosis and insulin insensitivity along the boundary between them. Eventually, the contents of fat cells that would otherwise have been digested by insulin are shed into the bloodstream. An inflammation response that mobilizes both T and B cells results in the creation of antibodies against these cells, causing them to become less responsive to insulin by an as-yet-unknown mechanism and promoting hypertension, hypertriglyceridemia, and arteriosclerosis, hallmarks of the metabolic syndrome. Obese mice administered anti-B cell CD-20 antibodies, however, did not become less responsive to insulin and as a result, did not develop diabetes mellitus or the metabolic syndrome, the posited mechanism being that anti-CD20 antibodies rendered the T cell antibodies dysfunctional and therefore powerless to cause insulin insensitivity by a B cell antibody-modulated autoimmune response. The protection afforded by anti-CD-20 lasted approximately forty days—the time it takes the body to replenish its supply of B cells—after which repetition was necessary to restore it. Hence, it has been argued that diabetes mellitus be reclassified as an autoimmune disease rather than a purely metabolic one and focus treatment for it on immune system modulation.{{cite web |url=https://www.lecturio.com/concepts/diabetes-mellitus/| title=Diabetes Mellitus == References ==